Recent price moves and performance snapshot

agilon health (AGL) has drawn investor attention after a recent pullback, with the stock closing at US$93.79 on 23 August 2026 and showing mixed short and longer term returns.

Over the past day, the share price declined 2.89%, and it was down 3.17% over the past week. The stock was also down 4.30% over the past month, while the past 3 months showed a gain of 9.99% and the 1 year total return was 1.72%.

So far this year, agilon health has recorded a 4.57% total return, and the 3 year and 5 year total returns reflected declines of 77.97% and 90.06% respectively. These mixed performance figures provide context for assessing how the business fundamentals and valuation may line up for investors watching the stock now.

For context, agilon health has seen its 90 day share price return of 9.99% give way to a recent loss of momentum, while the 1 year total shareholder return of 171.86% sits against much weaker multi year figures.

If you are assessing healthcare exposure beyond agilon health, it could be a good time to scan other specialists in the space using our curated list of 40 healthcare AI stocks

Bulls point to agilon health’s recent 90 day rebound and analyst price target gap, while bears highlight the multi year drawdown and current losses. Which side does today’s valuation actually support?

Most Popular Narrative: 15.4% Undervalued

agilon health closed at $93.79, while the most followed narrative places fair value at $110.92, so the current price sits well below that modelled estimate.

Strategic investments in advanced data analytics, AI-driven platforms, and enhanced burden-of-illness and quality assessment programs are improving the identification and management of high-risk patients, which should contribute to improved risk adjustment, better medical cost control, and higher net margins and earnings beginning in 2026.

Curious what kind of revenue path and margin turnaround would need to play out for agilon health to reach that fair value? The narrative leans on a specific earnings ramp, a higher profitability profile, and a richer future earnings multiple that is above the wider US healthcare sector. The full story shows how those moving parts are expected to work together over time.

Result: Fair Value of $110.92 (UNDERVALUED)

However, you also need to weigh agilon health’s ongoing losses and medical margin pressures, along with payer concentration and contract renegotiation risk that could undermine the bullish narrative.

Next Steps

With mixed signals around agilon health, it helps to move quickly from headline sentiment to your own view based on the underlying data and context. To see how the current concerns and potential upsides balance out, review the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond agilon health?

Do not stop your research with agilon health. The best opportunities often appear where you least expect them, and a quick screen could surface ideas you might otherwise miss.

• Target income strength with companies that feature resilient payouts using our list of 12 dividend fortresses.
• Hunt for quality at an appealing price by reviewing the 49 high quality undervalued stocks that pass strict fundamental checks.
• Pressure test your downside by focusing on 74 resilient stocks with low risk scores that combine financial resilience with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.